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ABSTRACT
Although resistance to quinolones is commonly chromosomally-encoded in Enterobacteriaceae, the
emergence of plasmid-mediated quinolone resistance (PMQR) has also been reported, with at least three
known resistance mechanisms to date, i.e., Qnr, aminoglycoside acetyltransferase AAC(6¢)-Ib-cr and
QepA. Qnr proteins protect target enzymes (DNA gyrase and type IV topoisomerase) from quinolone
inhibition, the AAC(6¢)-Ib-cr enzyme acetylates norﬂoxacin and ciproﬂoxacin, and the QepA efﬂux
pump extrudes hydrophilic ﬂuoroquinolones. Although these PMQR determinants confer only low-
level resistance to quinolones and ⁄ or ﬂuoroquinolones, they may provide a favourable background in
which the selection of additional chromosomally-encoded quinolone resistance mechanisms can occur.
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Resistance to quinolones and ﬂuoroquinolones
has been studied extensively among human and
veterinary isolates of bacteria during the last three
decades, with an increasing trend towards resis-
tance being related to heavy usage [1]. The
mechanisms of resistance to this antibiotic class
were considered originally to be only chromo-
somally-encoded, i.e., mostly involving impaired
drug targets (DNA gyrase and topoisomerase
IV), decreased outer-membrane permeability
(porin defects) and over-expression of naturally
occurring efﬂux systems [2]. Although thought to
be impossible because of the plasmid curing effect
of quinolones, plasmid-mediated quinolone resis-
tance (PMQR) was ﬁrst reported in 1998 in a
Klebsiella pneumoniae isolate from the USA [3].
The ﬁrst PMQR determinant (Qnr, lately
termed QnrA) is a protein with 218 amino-acids
that belongs to the family of pentapeptide repeat
proteins [3]. Two other Qnr-type determinants
have subsequently been discovered in Enterobac-
teriaceae, namely QnrB and QnrS, that share 40%
and 59% amino-acid identity, respectively, with
QnrA [4,5]. Qnr determinants may act by binding
directly to both DNA gyrase and topoisomerase
IV, thereby resulting in an absence of inhibition
by quinolones [6–8]. Qnr determinants confer
resistance to nalidixic acid, but only slightly
reduced susceptibility to ﬂuoroquinolones (a 16–
32-fold increase in MICs) [4,5]. From a clinical
point of view, Qnr determinants may increase the
mutant prevention concentration of ciproﬂoxacin
by more than ten-fold (from 0.2 to 3.2 mg ⁄L), thus
facilitating the recovery of mutants with higher
levels of resistance to quinolones [5]. Qnr-positive
isolates may therefore provide a favourable back-
ground in which in-vivo selection of additional
chromosome-borne mechanisms of resistance to
quinolones can occur during or after treatment
with ﬂuoroquinolones [9]. However, the expres-
sion of QnrA does not modify the bactericidal
activity of ﬂuoroquinolones [10].
The three types of Qnr determinants have now
been identiﬁed worldwide on all ﬁve continents
in many different enterobacterial species,
but mostly in both community and nosocomial
isolates of Escherichia coli, Enterobacter spp.,
Salmonella spp. and K. pneumoniae [4,5]. Their
overall prevalence may range from 0.2% to 50%,
depending on the criteria used to select
the strains investigated (e.g., resistance to
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ceftazidime, to nalidixic acid or to ﬂuoroquino-
lones) [5]. Interestingly, the QnrA and QnrB
determinants have often been associated with
plasmid-encoded expanded-spectrum b-lacta-
mases (SHV, CTX-M, or VEB-1 types) or AmpC
(FOX-5 and DHA-1 types), whereas QnrS has not
[4,5,11]. It has been shown that the Qnr determi-
nants probably originate in aquatic species of
bacteria, with Shewanella algae and Vibrio splendi-
dus being the progenitors of qnrA- and qnrS-like
genes [12,13]. The qnrS2 gene has also been
demonstrated recently in isolates of Aeromonas
spp. from the River Seine in Paris, which
emphasises the role of the aquatic environment
as a reservoir of PMQR [14].
Another type of PMQR determinant has been
discovered in qnrA-positive E. coli [15]. The
aac(6¢)-Ib-cr (for ciproﬂoxacin resistance) gene
encodes an aminoglycoside acetyltransferase
responsible for resistance to kanamycin, tobramy-
cin and amikacin. This variant possesses two
substitutions at codons 102 (Trp ﬁ Arg) and 179
(Asp ﬁ Tyr) as compared with the wild-type
AAC(6¢)-Ib enzyme [15]. Consequently, the vari-
ant enzyme acetylates ciproﬂoxacin and norﬂox-
acin, conferring slightly higher MICs (a two- to
four-fold increase) [15]. The expression of
AAC(6¢)-Ib-cr may facilitate the survival of DNA
gyrase and topoisomerase IV mutants, with an
increase in their mutant prevention concentration
from 0.2 to 3.2 mg ⁄L [5,15]. According to the few
surveys performed in Enterobacteriaceae, this
enzyme may be more widespread than Qnr
determinants, and is frequently associated with
the increasing problem of expanded-spectrum
b-lactamases, e.g., CTX-M-15, among commu-
nity-acquired enterobacterial isolates [16,17].
Very recently, a third type of PMQR determi-
nant has been identiﬁed in two E. coli clinical
isolates from Japan and Belgium [18,19]. The
qepA gene (for quinolones efﬂux pump) encodes
a protein that resembles a 14-transmembrane-
segment putative efﬂux pump belonging to the
major facilitator superfamily of proton-dependent
transporters [18,19]. This protein confers
resistance to the hydrophilic quinolones, e.g.,
norﬂoxacin, ciproﬂoxacin and enroﬂoxacin, with
a 32–64-fold increase in MIC [18]. To date, the
only provisional epidemiological data for QepA
have indicated that it has a low prevalence (0.3%)
(47th Interscience Conference on Antimicrobial
Agents and Chemotherapy, Chicago, 2007;
C2-158). A genetic linkage between the qepA gene
and the rmtB (an aminoglycoside ribosome meth-
yltransferase) gene has been demonstrated, and it
seems likely that these two genes are part of a
transposable element ﬂanked by two copies of
IS26 [19]. This suggests that there is potential for
selection of the QepA determinant by the use of
aminoglycosides, and of aminoglycoside resis-
tance by the use of quinolones.
The discovery of three major mechanisms of
PMQR within the last 10 years is peculiar. These
discoveries may reﬂect the emergence of novel
mechanisms of resistance, or simply a deeper
investigation of resistance mechanisms in clinical
isolates worldwide. Further studies may provide
the answers to several outstanding questions,
including the following: (i) what is the relation-
ship between quinolones in the environment
that are poorly biodegraded and the prevalence
of these resistance mechanisms? (ii) are other
PMQR mechanisms waiting to be discovered, e.g.,
is the quinolone hydroxylation resistance mecha-
nism demonstrated in some fungi capable of
being transfered to bacteria [20]? (iii) are these
resistance mechanisms really new and emerging
(retrospective prevalence studies will be needed
to answer this question)? (iv) what is the extent of
the spread of these resistance mechanisms in the
environment? and (v) of most importance, to
what extent will the presence of these resistance
mechanisms lead to clinical failure of quinolone-
and ⁄ or ﬂuoroquinolone-containing treatment
regimens?
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